Vaxart (VXRT) 10-K 15 Mar 23 2022 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2022	Mar. 14, 2023	Jun. 30, 2022
Document Information [Line Items]
Entity Central Index Key	0000072444
Entity Registrant Name	Vaxart, Inc.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2022
Document Transition Report	false
Entity File Number	001-35285
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	59-1212264
Entity Address, Address Line One	170 Harbor Way, Suite 300
Entity Address, City or Town	South San Francisco
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94080
City Area Code	650
Local Phone Number	550-3500
Title of 12(b) Security	Common Stock, $0.0001 par value
Trading Symbol	VXRT
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Public Float			$ 393,574,122
Entity Common Stock, Shares Outstanding		135,561,649
Auditor Name	WithumSmith+Brown, PC
Auditor Location	San Francisco, California
Auditor Firm ID	100

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash, cash equivalents and restricted cash	$ 46,013	$ 143,745
Short-term investments	49,704	22,742
Accounts receivable	20	71
Prepaid expenses and other current assets	3,714	2,609
Total current assets	99,451	169,167
Long-term investments	0	16,210
Property and equipment, net	15,585	6,601
Right-of-use assets, net	25,715	13,168
Intangible assets, net	5,020	10,624
Goodwill	4,508	4,508
Other long-term assets	3,568	890
Total assets	153,847	221,168
Current liabilities:
Accounts payable	5,514	3,872
Deferred grant revenue	2,000	0
Other accrued current liabilities	8,084	5,064
Current portion of operating lease liability	2,228	1,011
Current portion of liability related to sale of future royalties	95	836
Total current liabilities	17,921	10,783
Operating lease liability, net of current portion	19,477	11,997
Liability related to sale of future royalties, net of current portion	5,621	10,686
Other long-term liabilities	231	171
Total liabilities	43,250	33,637
Commitments and contingencies (Note 9)
Stockholders’ equity:
Preferred Stock: $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding as of December 31, 2022 or 2021	0	0
Common Stock: $0.0001 par value; 250,000,000 and 150,000,000 shares authorized as of December 31, 2022 and 2021, respectively; 134,199,429 and 125,594,393 shares issued and outstanding as of December 31, 2022 and 2021, respectively	13	13
Additional paid-in capital	437,992	406,943
Accumulated deficit	(327,109)	(219,351)
Accumulated other comprehensive loss	(299)	(74)
Total stockholders’ equity	110,597	187,531
Total liabilities and stockholders’ equity	$ 153,847	$ 221,168

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	250,000,000	150,000,000
Common stock, shares issued (in shares)	134,199,429	125,594,393
Common stock, shares outstanding (in shares)	134,199,429	125,594,393

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Revenue from Contract with Customer, Including Assessed Tax	$ 107	$ 892
Operating expenses:
Research and development	81,054	48,749
General and administrative	29,386	21,890
Impairment of intangible assets	4,254	3,005
Total operating expenses	114,694	73,644
Operating loss	(114,587)	(72,752)
Other income (expense):
Interest income	1,247	81
Non-cash interest expense related to sale of future royalties	(1,305)	(1,480)
Gain on remeasurement of future royalty liability	6,960	3,789
Foreign exchange loss, net	(6)	(1)
Loss before income taxes	(107,691)	(70,363)
Provision for income taxes	67	107
Net loss	$ (107,758)	$ (70,470)
Net loss per share attributable to common stockholders, basic and diluted (in dollars per share)	$ (0.84)	$ (0.58)
Shares used to compute net loss per share, basic and diluted (in shares)	127,683,813	121,453,723
Comprehensive loss:
Net loss	$ (107,758)	$ (70,470)
Unrealized loss on available-for-sale investments, net of tax	(225)	(74)
Comprehensive loss	(107,983)	(70,544)
Customer Service Contracts [Member]
Revenue from Contract with Customer, Including Assessed Tax	0	13
Non Cash Royalty Revenue [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 107	$ 879

Condensed Consolidated Statemen

Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balances (in shares) at Dec. 31, 2020	110,271,093
Balances at Dec. 31, 2020	$ 11	$ 272,274	$ (148,881)	$ 0	$ 123,404
Issuance of common stock (in shares)	13,239,839
Issuance of common stock	$ 2	122,208	0	0	122,210
Issuance of common stock upon exercise of common stock warrants (in shares)	1,012,540
Issuance of common stock upon exercise of common stock warrants	$ 0	1,849	0	0	$ 1,849
Issuance of common stock upon exercise of options (in shares)	1,070,921				1,070,921
Issuance of common stock upon exercise of options	$ 0	1,745	0	0	$ 1,745
Stock-based compensation	0	8,867	0	0	8,867
Unrealized gains (losses) on available-for-sale investments	0	0	0	(74)	(74)
Net loss	0	0	(70,470)	0	(70,470)
Issuance of common stock upon exercise of common stock warrants	$ 0	1,849	0	0	1,849
Balances (in shares) at Dec. 31, 2021	125,594,393
Balances at Dec. 31, 2021	$ 13	406,943	(219,351)	(74)	187,531
Issuance of common stock (in shares)	8,419,700
Issuance of common stock	$ 0	17,237	0	0	17,237
Issuance of common stock upon exercise of common stock warrants (in shares)	5,000
Issuance of common stock upon exercise of common stock warrants	$ 0	2	0	0	$ 2
Issuance of common stock upon exercise of options (in shares)	180,336				180,336
Issuance of common stock upon exercise of options	$ 0	223	0	0	$ 223
Stock-based compensation	0	13,587	0	0	13,587
Unrealized gains (losses) on available-for-sale investments	0	0	0	(225)	(225)
Net loss	0	0	(107,758)	0	(107,758)
Issuance of common stock upon exercise of common stock warrants	$ 0	2	0	0	2
Balances (in shares) at Dec. 31, 2022	134,199,429
Balances at Dec. 31, 2022	$ 13	$ 437,992	$ (327,109)	$ (299)	$ 110,597

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Parentheticals) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Offering costs	$ 786	$ 5,752

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities:
Net loss	$ (107,758,000)	$ (70,470,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	5,805,000	4,208,000
Accretion of (discount) premium on investments	(163,000)	85,000
Impairment of intangible assets	4,254,000	3,005,000
Stock-based compensation	13,587,000	8,867,000
Gain on remeasurement of future royalty liability	(6,960,000)	(3,789,000)
Non-cash interest expense related to sale of future royalties	1,305,000	1,480,000
Non-cash revenue related to sale of future royalties	(151,000)	(1,098,000)
Change in operating assets and liabilities:
Accounts receivable	51,000	263,000
Prepaid expenses and other assets	(3,783,000)	(1,800,000)
Accounts payable	357,000	1,626,000
Deferred grant revenue	2,000,000	0
Accrued liabilities	(3,323,000)	(2,209,000)
Net cash used in operating activities	(94,779,000)	(59,832,000)
Cash flows from investing activities:
Purchase of property and equipment	(9,601,000)	(5,157,000)
Acquisition of business, net of cash acquired	0	(4,829,000)
Purchases of investments	(55,014,000)	(44,811,000)
Proceeds from maturities of investments	44,200,000	5,700,000
Net cash used in investing activities	(20,415,000)	(49,097,000)
Cash flows from financing activities:
Net proceeds from issuance of common stock through at-the-market facilities	17,237,000	122,210,000
Proceeds from issuance of common stock upon exercise of common stock warrants	2,000	1,849,000
Proceeds from issuance of common stock upon exercise of stock options	223,000	1,745,000
Net cash provided by financing activities	17,462,000	125,804,000
Net (decrease) increase in cash, cash equivalents and restricted cash	(97,732,000)	16,875,000
Cash, cash equivalents and restricted cash at beginning of the period	143,745,000	126,870,000
Cash, cash equivalents and restricted cash at end of the period	46,013,000	143,745,000
Supplemental disclosure of non-cash investing and financing activity:
Operating lease liabilities arising from obtaining right-of-use assets	9,997,000	8,395,000
Lease-related assets and liabilities derecognized on early termination and modification of leases	0	321,000
Acquisition of property and equipment included in accounts payable and accrued expenses	1,803,000	453,000
Cash and cash equivalents	44,013,000	143,745,000
Restricted cash	2,000,000	0
Cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows	$ 46,013,000	$ 143,745,000

Note 1 - Organization and Natur

Note 1 - Organization and Nature of Business	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. General Vaxart Biosciences, Inc. was originally incorporated in California in March 2004, July 2007, February 2018, On October 13, 2020, “October 2020 October 13, 2020, In the year ended December 31, 2021, October 2020 October 2020 December 31, 2022 2021, October 2020 On September 13, 2021, October 2020 September 15, 2021, “September 2021 may September 16, 2021, December 31, 2022 September 2021 The Company’s principal operations are based in South San Francisco, California, and it operates in one

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Basis of Presentation, Liquidity and Going Concern The Company is a clinical-stage biotechnology company with no December 31, 2022, 2022 no Subsequent to December 31, 2022, 15 second 2024. The Company will be dependent upon raising additional capital through placement of its common stock, notes or other securities, borrowings, or entering into a partnership with a strategic party in order to implement its business plan. There can be no The financial statements do not Basis of Consolidation Use of Estimates 2 Foreign Currencies no Cash, Cash Equivalents and Restricted Cash three may December 31, 2022 2021 zero Investments may three The Company determines the appropriate classification of its investments in marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. Marketable debt securities are classified and accounted for as available-for-sale. After consideration of the Company’s objectives to preserve capital, as well as its liquidity requirements, it may 12 12 12 12 Securities are evaluated for impairment at the end of each reporting period. Impairment is evaluated considering numerous factors, including whether a decline in fair value below the amortized cost basis is due to credit-related factors or non-credit-related factors, the financial condition and near-term prospects of the issuer, and intent and ability to hold the investment to allow for an anticipated recovery in fair value. A credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings. Any impairment that is not Concentration of Credit Risk The primary focus of the Company’s investment strategy is to preserve capital and meet liquidity requirements. The Company’s investment policy addresses the level of credit exposure by limiting the concentration in any one Accounts Receivable no December 31, 2022 2021 Property and Equipment The useful lives of the property and equipment are as follows: Laboratory equipment (in years) 5 Office and computer equipment (in years) 3 Leasehold improvements Shorter of remaining lease term or estimated useful life Goodwill and Other Intangible Assets not Impairment of Long-Lived Assets fourth may not December 31, 2022 2021 7 Accrued Clinical and Manufacturing Expenses third not The Company estimates the amount of services provided through discussions with internal personnel and external service providers as to the progress or stage of completion of the services and the agreed-upon fee to be paid for such services. The Company makes significant judgments and estimates in determining the accrued balance in each reporting period. As actual costs become known, it adjusts its accrued estimates. Although the Company does not may third not Leases one not not Revenue Recognition five (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account. Revenue from royalties earned as a percentage of sales, including milestone payments based on achieving a specified level of sales, where a license is deemed to be the predominant item to which the royalties relate, is recognized as revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied), as required under the sales- and usage-based royalty exception. Revenue from contracts with customers is recognized ratably, based on costs incurred, as the Company provides promised services to its customers in amounts that reflect the consideration that the Company expects to receive for those services. In 2022, no December 31, 2022. Under cost reimbursable contracts, the Company recognizes revenue as allowable costs are incurred and the fixed fee is earned. Reimbursable costs under the contract primarily include direct labor, subcontract costs, materials, equipment, travel, and approved overhead and indirect costs. Fixed fees under cost reimbursable contracts are earned in proportion to the allowable costs incurred in performance of the work relative to total estimated contract costs, with such costs incurred representing a reasonable measurement of the proportional performance of the work completed. Payments to the Company under cost reimbursable contracts, such as this contract, are provisional payments subject to adjustment upon annual audit by the government. Management believes that revenue for periods not may Research and Development Costs third Stock-Based Compensation may Net Income (Loss) Per Share Diluted net income (loss) per common share is computed giving effect to all potential dilutive common shares, comprising common stock issuable upon exercise of stock options, warrants, RSUs and ESPP. The Company uses the treasury-stock method to compute diluted income (loss) per share with respect to its stock options, warrants, RSUs and ESPP. For purposes of this calculation, options, warrants, RSUs and ESPP plan grants to purchase common stock are considered to be potential common shares and are only included in the calculation of diluted net income per share when their effect is dilutive. In the event of a net loss, the effects of all potentially dilutive shares are excluded from the diluted net loss per share calculation as their inclusion would be antidilutive. Recent Accounting Pronouncements The Company has reviewed all significant newly-issued accounting pronouncements that are not not not

Note 3 - Business Combination

Note 3 - Business Combination	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Business Combination Disclosure [Text Block]	NOTE 3. On November 30, 2021, December 31, 2021. The fair value of the assets acquired in connection with the acquisition are as follows (in thousands): Property and equipment $ 321 Goodwill 4,508 Total purchase price $ 4,829 In addition, the Company paid $671,000 in prepaid rent in connection with the modification of the pre-existing embedded lease at the Burlingame facility (see Note 8 Goodwill, which represents the excess of the purchase price over the fair value of assets acquired, is attributable primarily to the expected cost savings of manufacturing internally, as opposed to outsourcing, and the assembled workforce. All of the goodwill is expected to be deductible for income tax purposes.

Note 4 - Fair Value of Financia

Note 4 - Fair Value of Financial Instruments	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Fair Value Disclosures [Text Block]	NOTE 4. Fair value accounting is applied for all financial assets and liabilities and nonfinancial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). Financial instruments include cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued liabilities that approximate fair value due to their relatively short maturities. Assets and liabilities recorded at fair value on a recurring basis in the consolidated balance sheets are categorized based upon the level of judgment associated with inputs used to measure their fair values. The accounting guidance for fair value provides a framework for measuring fair value and requires certain disclosures about how fair value is determined. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance also establishes a three The three Level 1 Level 2 not Level 3 no The following table sets forth the fair value of the Company’s financial assets that are measured on a recurring basis as of December 31, 2022 2021 Level 1 Level 2 Level 3 Total December 31, 2022 Financial assets: Money market funds $ 30,834 $ — $ — $ 30,834 U.S. Treasury securities — 41,542 — 41,542 Commercial paper — 5,674 — 5,674 Corporate debt securities — 2,488 — 2,488 Total assets $ 30,834 $ 49,704 $ — $ 80,538 Level 1 Level 2 Level 3 Total December 31, 2021 Financial assets: Money market funds $ 70,978 $ — $ — $ 70,978 U.S. Treasury securities — 24,997 — 24,997 Commercial paper — 7,491 — 7,491 Corporate debt securities — 6,464 — 6,464 Total assets $ 70,978 $ 38,952 $ — $ 109,930 The Company held no financial liabilities measured on a recurring basis as of December 31, 2022 2021 December 31, 2022 2021.

Note 5 - Balance Sheet Componen

Note 5 - Balance Sheet Components	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Supplemental Balance Sheet Disclosures [Text Block]	NOTE 5. (a) Cash, Cash Equivalents, Restricted Cash and Investments Cash, cash equivalents, restricted cash and investments consisted of the following (in thousands): Amortized Gross Unrealized Estimated Cash, Cash Equivalents Short-Term Long-Term Cost Gains Losses Fair Value and Restricted Cash Investments Investments December 31, 2022 Cash at banks $ 15,179 $ — $ — $ 15,179 $ 15,179 $ — $ — Money market funds 30,834 — — 30,834 30,834 — — U.S. Treasury securities 41,812 — (270 ) 41,542 — 41,542 — Commercial paper 2,488 — — 2,488 — 2,488 — Corporate debt securities 5,703 — (29 ) 5,674 — 5,674 — Total $ 96,016 $ — $ (299 ) $ 95,717 $ 46,013 $ 49,704 $ — Amortized Gross Unrealized Estimated Cash and Cash Short-Term Long-Term Cost Gains Losses Fair Value Equivalents Investments Investments December 31, 2021 Cash at banks $ 72,767 $ — $ — $ 72,767 $ 72,767 $ — $ — Money market funds 70,978 — — 70,978 70,978 — — U.S. Treasury securities 25,055 — (58 ) 24,997 — 12,022 12,975 Commercial paper 7,491 — — 7,491 — 7,491 — Corporate debt securities 6,480 — (16 ) 6,464 — 3,229 3,235 Total $ 182,771 $ — $ (74 ) $ 182,697 $ 143,745 $ 22,742 $ 16,210 (b) Accounts Receivable Accounts receivable comprises royalties receivable of $20,000 and $71,000 as of December 31, 2022 2021 December 31, 2022 2021 (c) Property and Equipment, Net Property and equipment, net consists of the following (in thousands): December 31, 2022 December 31, 2021 Laboratory equipment $ 12,035 $ 5,057 Office and computer equipment 1,078 481 Leasehold improvements 1,760 1,063 Construction in progress 3,984 1,305 Total property and equipment 18,857 7,906 Less: accumulated depreciation (3,272 ) (1,305 ) Property and equipment, net $ 15,585 $ 6,601 Depreciation expense was $1,967,000, and $732,000 the years ended December 31, 2022 2021, December 31, 2022 2021 (d) Right-of-Use Assets, Net Right-of-use assets, net comprises facilities of $25.7 million and $13.2 million as of December 31, 2022 2021, one 2022, 8 (e) Intangible Assets, Net Intangible assets comprise developed technology, intellectual property and, until it was considered fully impaired, in-process research and development. Intangible assets are carried at cost less accumulated amortization. Amortization is computed using the straight-line method over useful life of 11.75 years for developed technology and 20 years for intellectual property. As of December 31, 2022 December 31, 2022 December 31, 2021 Developed technology $ 5,000 $ 10,600 Intellectual property 80 80 Total cost 5,080 10,680 Less: accumulated amortization (60 ) (56 ) Intangible assets, net $ 5,020 $ 10,624 Intangible asset amortization expense was $1.3 million and $1.7 million for the years ended December 31, 2022 2021, 19 7 December 31, 2022 2021, As of December 31, 2022 Year Ending December 31, Amount 2023 $ 731 2024 731 2025 731 2026 731 2027 731 Thereafter 1,365 Total $ 5,020 (f) Goodwill Goodwill, which represents the excess of the purchase price over the fair value of assets acquired, comprises $4.5 million for both years ended December 31, 2022 2021 December 31, 2022 December 31, 2021, 2021 4. December 31, 2022 2021, no (g) Other Accrued Liabilities Other accrued liabilities consist of the following (in thousands): December 31, 2022 December 31, 2021 Accrued compensation $ 3,112 $ 2,786 Accrued clinical and manufacturing expenses 2,413 986 Accrued professional and consulting services 691 556 Accrued other expenses 1,868 736 Total $ 8,084 $ 5,064

Note 6 - Revenue

Note 6 - Revenue	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Revenue [Text Block]	NOTE 6. Royalty agreement The Company generates royalty revenue from the sale of Inavir in Japan, pursuant to a collaboration and license agreement that Aviragen entered into with Daiichi Sankyo Company, Limited (“Daiichi Sankyo”), in 2009. September 2010, December 2029 2022 2021, nil. 7 2022 2021, December 31, 2022 2021,

Note 7 - Liabilities Related to

Note 7 - Liabilities Related to Sale of Future Royalties	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Liabilities Related to Sale of Future Royalties [Text Block]	7. In April 2016, first April 1, Under the relevant accounting guidance, due to a limit on the amount of royalties that HCRP can earn under the RIAA, this transaction was accounted for as a liability that is being amortized using the effective interest method over the life of the arrangement. The Company has no not not The following table shows the activity within the liability account during the year ended December 31, 2022 ( Total liability related to sale of future royalties, start of year $ 11,522 Non-cash royalty revenue paid to HCRP (151 ) Non-cash interest expense recognized 1,305 Revaluation gain recognized (6,960 ) Total liability related to sale of future royalties, end of year 5,716 Current portion (95 ) Long-term portion $ 5,621 Due to a decline in royalties earned since the outbreak of COVID- 19, December 31, 2022 2021,

Note 8 - Leases

Note 8 - Leases	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	8. The Company has obtained the right of use for office and manufacturing facilities under six operating lease agreements with initial terms exceeding one two one one The Company obtained the right of use of real estate located in South San Francisco, California, in November 2020 September 30, 2025, March 31, 2029, no June 2015 April 30, 2020, five July 2019, April 30, 2025, March 31, 2029, eight September 2021 March 31, 2029, eight three September 30, 2022, first 2023. December 31, 2022, no March 30, 2029, five May 31, 2025, two one As of December 31, 2022 one The following table summarizes the Company’s undiscounted cash payment obligations for its operating lease liabilities with initial terms of more than twelve December 31, 2022 Year Ending December 31, Amount 2023 $ 4,072 2024 4,213 2025 4,356 2026 4,964 2027 5,138 Thereafter 6,649 Undiscounted total 29,392 Less: imputed interest (7,687 ) Present value of future minimum payments 21,705 Current portion of operating lease liability (2,228 ) Operating lease liability, net of current portion $ 19,477 The Company has future obligations of $29.4 million for facilities. The Company presently has no finance leases. Certain operating lease agreements for facilities include non-lease costs, such as common area maintenance, which are recorded as variable lease costs. Operating lease expenses for the years ended December 31, 2022 2021, one not Year Ended December 31, 2022 2021 Lease cost Operating lease cost $ 4,159 $ 2,513 Short-term lease cost 436 340 Variable lease cost 1,312 1,233 Sublease income - (36 ) Total lease cost $ 5,907 $ 4,050

Note 9 - Commitments and Contin

Note 9 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 9. (a) Purchase Commitments As of December 31, 2022 Note 8 March 31, 2029, not (b) Indemnifications In the ordinary course of business, the Company enters into agreements that may may third not may may (c) From time to time the Company may On August 4, 2020, Godfrey v. Latour, et al. September 4, 2020 Ennis v. Latour, et al second November 25, 2020. third June 11, 2021. third third third June 2020; April 24, 2020, two June 8, 2020. third no August 31, 2021, third November 17, 2022, In August September 2020, two first Himmelberg v. Vaxart, Inc. et al. August 24, 2020. second Hovhannisyan v. Vaxart, Inc. et al. September 1, 2020 ( September 17, 2020, two December 9, 2020, On January 29, 2021, July 8, 2021, May 14, 2021, June 10, 2021, first August 9, 2021, first first three 10 10b 5, 20 20A first first July 8, 2021, first December 22, 2021, July 27, 2022, $2.0 November 2, 2022, November 14, 2022, second January 25, 2023, On October 23, 2020, Roth v. Armistice Capital LLC, et al. 16 On January 8, 2021, pro se Chan v. Vaxart, Inc. et al.

Note 10 - Stockholders' Equity

Note 10 - Stockholders' Equity	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 10. (a) Preferred Stock The Company is authorized to issue 5,000,000 shares of preferred stock, $0.0001 par value per share. The Company’s board of directors may, 5,000,000 one may no (b) Common Stock As of December 31, 2022 August 4, 2022, one may no December 31, 2022 In the event of the Company’s voluntary or involuntary liquidation, dissolution, distribution of assets or winding-up, the holders of the common stock will be entitled to receive an equal amount per share of all the Company’s assets of whatever kind available for distribution to stockholders, after the rights of the holders of the preferred stock have been satisfied. There are no The Company had shares of common stock reserved for issuance as follows: December 31, 2022 December 31, 2021 Options issued and outstanding 14,725,261 10,216,106 RSUs issued and outstanding 808,310 — Available for future grants of equity awards 12,074,692 5,582,742 Common stock warrants 227,434 232,434 2022 Employee Stock Purchase Plan 1,800,000 — Total 29,635,697 16,031,282 (c) Warrants The Company has the following warrants outstanding as of December 31, 2022 none Securities into which warrants are convertible Warrants outstanding Exercise Price Expiration Date Common Stock 44,148 $ 1.10 April 2024 Common Stock 26,515 $ 1.375 April 2024 Common Stock 29,150 $ 2.50 March 2025 Common Stock 100,532 $ 3.125 February 2025 Common Stock 16,175 $ 3.125 March 2024 Common Stock 10,914 $ 22.99 December 2026 Total 227,434 In the event of a Fundamental Transaction (a transfer of ownership of the Company as defined in the warrant) within the Company’s control, the holders of the unexercised common stock warrants exercisable for $1.10 and $2.50 and those exercisable for $3.125 expiring in February 2025 not

Note 11 - Equity Incentive Plan

Note 11 - Equity Incentive Plans	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	NOTE 11. On April 23, 2019, 2019 “2019 may 2019 may 2019 not 2019 The aggregate number of shares of common stock authorized for issuance under the 2019 2019 June 8, 2020, June 16, 2021, August 4, 2022, 2019 2019 ten may During the year ended December 31, 2022, four three A summary of stock option and RSU transactions in each of the two December 31, 2022 2021 Weighted Weighted Shares Number of Option Average Number of RSU Average Available Options Exercise RSUs Grant Date For Grant Outstanding Price Outstanding Fair Value Balance at January 1, 2021 1,230,863 6,813,033 $ 2.70 — $ — Authorized under 2019 Plan Amendment 8,900,000 — $ — — $ — Granted (5,178,438 ) 5,178,438 $ 7.09 — $ — Exercised — (1,070,921 ) $ 1.63 — $ — Forfeited 630,317 (650,054 ) $ 3.16 — $ — Canceled — (54,390 ) $ 11.98 — $ — Balance at December 31, 2021 5,582,742 10,216,106 $ 4.96 — $ — Authorized under 2019 Plan Amendment 12,000,000 — $ — — $ — Granted (7,291,935 ) 6,376,657 $ 4.10 915,278 $ 3.58 Exercised — (180,336 ) $ 1.24 — $ — Forfeited 1,625,133 (1,518,230 ) $ 6.19 (106,968 ) $ 3.62 Canceled 158,752 (168,936 ) $ 7.17 — $ — Balance at December 31, 2022 12,074,692 14,725,261 $ 4.48 808,310 $ 3.57 As of December 31, 2022 The aggregate intrinsic value represents the total pre-tax value (i.e., the difference between the Company’s stock price and the exercise price) of stock options outstanding as of December 31, 2022 The Company received $223,000 for the 180,336 options exercised during the year ended December 31, 2022 December 31, 2021, The weighted average grant date fair value of options awarded in the years ended December 31, 2022 2021, Year Ended December 31, 2022 2021 Risk-free interest rate 1.62% - 4.02 % 0.91% - 1.35 % Expected term (in years) 5.42 - 6.08 5.44 - 6.08 Expected volatility 125% - 131 % 122% - 131 % Dividend yield — % — % The Company measures the fair value of all stock-based awards on the grant date and records the fair value of these awards, net of estimated forfeitures, to compensation expense over the service period. Total stock-based compensation recognized for options was as follows (in thousands): Year Ended December 31, 2022 2021 Research and development $ 9,183 $ 4,304 General and administrative 4,404 4,563 Total stock-based compensation $ 13,587 $ 8,867 Effective June 16, 2021, three ten June 16, 2023. three June 30, 2021. As of December 31, 2022 On August 4, 2022, 2022 “2022 6 one 85% 6 No December 31, 2022, The fair value of the ESPP shares is estimated using the Black-Scholes option pricing model. The weighted average estimated fair value for shares issued under our ESPP in fiscal years 2022 December 31, 2022 nil.

Note 12 - Benefit Plan

Note 12 - Benefit Plan	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Retirement Benefits [Text Block]	NOTE 12. The Company provides a tax-qualified employee savings and retirement plan commonly known as a 401 may $20,500 2022 $19,500 2021. 50 may $6,500 2022 2021. Employees direct their contributions, which vest immediately, across a series of mutual funds. In the years ended December 31, 2022 2021, December 31, 2022 2021, December 31, 2022 2021,

Note 13 - Income Taxes

Note 13 - Income Taxes	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Income Tax Disclosure [Text Block]	NOTE 13. The provision for income taxes consists of the following (in thousands): Year Ended December 31, 2022 2021 Current: Federal $ — $ — State 3 1 Foreign 64 106 Total Current 67 107 Deferred: Federal — — State — — Foreign — — Total Deferred — — Provision for income taxes $ 67 $ 107 The components of the deferred tax assets are as follows (in thousands): December 31, 2022 December 31, 2021 Deferred tax assets: Net operating loss carryforwards $ 39,822 $ 30,256 Research and development tax credits 7,943 4,923 Capitalized research and development 14,260 4,016 Sale of future royalties 2,886 5,826 Lease liability 4,581 3,184 Accruals, reserves and other 5,004 3,043 Total deferred tax assets 74,496 51,248 Valuation allowance (66,323 ) (42,589 ) Deferred tax assets net of valuation allowance 8,173 8,659 Deferred tax liabilities: Intangible assets (2,614 ) (5,410 ) Right-of-use assets (5,427 ) (3,223 ) Depreciation on property and equipment (132 ) (26 ) Total deferred tax liabilities (8,173 ) (8,659 ) Net deferred tax assets $ — $ — A reconciliation of the provision for income taxes with the expected provision for income taxes computed by applying the federal statutory income tax rate of 21% Year Ended December 31, 2022 2021 U.S. federal taxes at statutory rate 21.0 % 21.0 % State taxes (net of federal benefit) 0.1 4.0 Foreign rate differential (0.3 ) 0.3 Permanently non-deductible items (1.5 ) 0.2 Tax credits 3.0 3.4 Change in valuation allowance (22.0 ) (29.3 ) Tax attributes write-off due to change in control — — Prior year true-up (0.2 ) 0.6 Other (0.2 ) (0.3 ) Provision for income taxes (0.1 )% (0.1 )% The Company’s actual tax expense differed from the statutory federal income tax expense using a tax rate of 21% for the years ended December 31, 2022 2021, As of December 31, 2022 2021, not 2024 2028 As of December 31, 2022 not may not As of December 31, 2022 2021, 2039. not Beginning on January 1, 2022, December 2017, five fifteen not Sections 382 383 not 382 383 not The Company is required to reduce its deferred tax assets by a valuation allowance if it is more likely than not not December 31, 2022 2021. December 31, 2022 2021, The Company records unrecognized tax benefits, where appropriate, for all uncertain income tax positions. The Company recorded unrecognized tax benefits for uncertain tax positions of approximately $4.9 million and $2.4 million as of December 31, 2022 2021 none A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands): Year Ended December 31, 2022 2021 Beginning Balance $ 2,422 $ 1,281 Additions based on tax positions related to the current year 2,589 1,132 Increase (decreases) related to prior years’ tax positions (66 ) 9 Ending Balance $ 4,945 $ 2,422 The Company’s policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. During the year ended December 31, 2022 2021, no twelve The Company files income tax returns in the U.S, Australia, as well as with various U.S. states. The Company is subject to tax audits in all jurisdictions in which it files income tax returns. Tax audits by their very nature are often complex and can require several years to complete. There are currently no Under the tax statute of limitations applicable to the Internal Revenue Code, the Company and its U.S. subsidiary, either standalone or as part of the consolidated group, is no 2017. no 2016 2004 2015

Note 14 - Net Loss Per Share At

Note 14 - Net Loss Per Share Attributable to Common Stockholders	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Earnings Per Share [Text Block]	NOTE 14. The following table presents the calculation of basic and diluted net loss per share (in thousands, except share and per share amounts): Year Ended December 31, 2022 2021 Net loss $ (107,758 ) $ (70,470 ) Shares used to compute net loss per share, basic and diluted 127,683,813 121,453,723 Net loss per share attributable to common stockholders, basic and diluted $ (0.84 ) $ (0.58 ) No adjustment has been made to the net loss attributable to common stockholders as the effect would be anti-dilutive due to the net loss. The following potentially dilutive weighted average securities were excluded from the computation of weighted average shares outstanding because they would have been antidilutive: Year Ended December 31, 2022 2021 Options to purchase common stock 13,567,390 8,206,137 Restricted stock unit to purchase common stock 460,975 — Warrants to purchase common stock 228,725 369,043 Employee Stock Purchase Plan 392,095 — Total potentially dilutive securities excluded from denominator of the diluted earnings per share computation 14,649,185 8,575,180

Note 15 - Subsequent Events

Note 15 - Subsequent Events	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 15. Since December 31, 2022 September 2021 1 March 14, 2023 Changes in the status of litigation since December 31, 2022, 9. Litigation In the first 2023, 2 27% In light of the recent situation affecting Silicon Valley Bank, N.A. (“SVB”), including the Federal Deposit Insurance Corporation takeover of SVB, the Company decided to move any cash or other deposits previously held at SVB to larger financial institutions. We have access to all of our cash and other deposits previously held at SVB. We do not

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation, Liquidity and Going Concern The Company is a clinical-stage biotechnology company with no December 31, 2022, 2022 no Subsequent to December 31, 2022, 15 second 2024. The Company will be dependent upon raising additional capital through placement of its common stock, notes or other securities, borrowings, or entering into a partnership with a strategic party in order to implement its business plan. There can be no The financial statements do not
Consolidation, Policy [Policy Text Block]	Basis of Consolidation
Use of Estimates, Policy [Policy Text Block]	Use of Estimates 2
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currencies no
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash, Cash Equivalents and Restricted Cash three may December 31, 2022 2021 zero
Investment, Policy [Policy Text Block]	Investments may three The Company determines the appropriate classification of its investments in marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. Marketable debt securities are classified and accounted for as available-for-sale. After consideration of the Company’s objectives to preserve capital, as well as its liquidity requirements, it may 12 12 12 12 Securities are evaluated for impairment at the end of each reporting period. Impairment is evaluated considering numerous factors, including whether a decline in fair value below the amortized cost basis is due to credit-related factors or non-credit-related factors, the financial condition and near-term prospects of the issuer, and intent and ability to hold the investment to allow for an anticipated recovery in fair value. A credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings. Any impairment that is not
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk The primary focus of the Company’s investment strategy is to preserve capital and meet liquidity requirements. The Company’s investment policy addresses the level of credit exposure by limiting the concentration in any one
Receivable [Policy Text Block]	Accounts Receivable no December 31, 2022 2021
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment The useful lives of the property and equipment are as follows: Laboratory equipment (in years) 5 Office and computer equipment (in years) 3 Leasehold improvements Shorter of remaining lease term or estimated useful life
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Goodwill and Other Intangible Assets not
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets fourth may not December 31, 2022 2021 7
Accrued Clinical And Manufacturing Expenses Policy [Policy Text Block]	Accrued Clinical and Manufacturing Expenses third not The Company estimates the amount of services provided through discussions with internal personnel and external service providers as to the progress or stage of completion of the services and the agreed-upon fee to be paid for such services. The Company makes significant judgments and estimates in determining the accrued balance in each reporting period. As actual costs become known, it adjusts its accrued estimates. Although the Company does not may third not
Lessee, Leases [Policy Text Block]	Leases one not not
Revenue [Policy Text Block]	Revenue Recognition five (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account. Revenue from royalties earned as a percentage of sales, including milestone payments based on achieving a specified level of sales, where a license is deemed to be the predominant item to which the royalties relate, is recognized as revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied), as required under the sales- and usage-based royalty exception. Revenue from contracts with customers is recognized ratably, based on costs incurred, as the Company provides promised services to its customers in amounts that reflect the consideration that the Company expects to receive for those services. In 2022, no December 31, 2022. Under cost reimbursable contracts, the Company recognizes revenue as allowable costs are incurred and the fixed fee is earned. Reimbursable costs under the contract primarily include direct labor, subcontract costs, materials, equipment, travel, and approved overhead and indirect costs. Fixed fees under cost reimbursable contracts are earned in proportion to the allowable costs incurred in performance of the work relative to total estimated contract costs, with such costs incurred representing a reasonable measurement of the proportional performance of the work completed. Payments to the Company under cost reimbursable contracts, such as this contract, are provisional payments subject to adjustment upon annual audit by the government. Management believes that revenue for periods not may
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs third
Share-Based Payment Arrangement [Policy Text Block]	Stock-Based Compensation may
Earnings Per Share, Policy [Policy Text Block]	Net Income (Loss) Per Share Diluted net income (loss) per common share is computed giving effect to all potential dilutive common shares, comprising common stock issuable upon exercise of stock options, warrants, RSUs and ESPP. The Company uses the treasury-stock method to compute diluted income (loss) per share with respect to its stock options, warrants, RSUs and ESPP. For purposes of this calculation, options, warrants, RSUs and ESPP plan grants to purchase common stock are considered to be potential common shares and are only included in the calculation of diluted net income per share when their effect is dilutive. In the event of a net loss, the effects of all potentially dilutive shares are excluded from the diluted net loss per share calculation as their inclusion would be antidilutive.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements The Company has reviewed all significant newly-issued accounting pronouncements that are not not not

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Property, Plant, and Equipment, Useful Life [Table Text Block]	Laboratory equipment (in years) 5 Office and computer equipment (in years) 3 Leasehold improvements Shorter of remaining lease term or estimated useful life

Note 3 - Business Combination (

Note 3 - Business Combination (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	Property and equipment $ 321 Goodwill 4,508 Total purchase price $ 4,829

Note 4 - Fair Value of Financ_2

Note 4 - Fair Value of Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	Level 1 Level 2 Level 3 Total December 31, 2022 Financial assets: Money market funds $ 30,834 $ — $ — $ 30,834 U.S. Treasury securities — 41,542 — 41,542 Commercial paper — 5,674 — 5,674 Corporate debt securities — 2,488 — 2,488 Total assets $ 30,834 $ 49,704 $ — $ 80,538 Level 1 Level 2 Level 3 Total December 31, 2021 Financial assets: Money market funds $ 70,978 $ — $ — $ 70,978 U.S. Treasury securities — 24,997 — 24,997 Commercial paper — 7,491 — 7,491 Corporate debt securities — 6,464 — 6,464 Total assets $ 70,978 $ 38,952 $ — $ 109,930

Note 5 - Balance Sheet Compon_2

Note 5 - Balance Sheet Components (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Cash, Cash Equivalents and Investments [Table Text Block]	Amortized Gross Unrealized Estimated Cash, Cash Equivalents Short-Term Long-Term Cost Gains Losses Fair Value and Restricted Cash Investments Investments December 31, 2022 Cash at banks $ 15,179 $ — $ — $ 15,179 $ 15,179 $ — $ — Money market funds 30,834 — — 30,834 30,834 — — U.S. Treasury securities 41,812 — (270 ) 41,542 — 41,542 — Commercial paper 2,488 — — 2,488 — 2,488 — Corporate debt securities 5,703 — (29 ) 5,674 — 5,674 — Total $ 96,016 $ — $ (299 ) $ 95,717 $ 46,013 $ 49,704 $ — Amortized Gross Unrealized Estimated Cash and Cash Short-Term Long-Term Cost Gains Losses Fair Value Equivalents Investments Investments December 31, 2021 Cash at banks $ 72,767 $ — $ — $ 72,767 $ 72,767 $ — $ — Money market funds 70,978 — — 70,978 70,978 — — U.S. Treasury securities 25,055 — (58 ) 24,997 — 12,022 12,975 Commercial paper 7,491 — — 7,491 — 7,491 — Corporate debt securities 6,480 — (16 ) 6,464 — 3,229 3,235 Total $ 182,771 $ — $ (74 ) $ 182,697 $ 143,745 $ 22,742 $ 16,210
Property, Plant and Equipment [Table Text Block]	December 31, 2022 December 31, 2021 Laboratory equipment $ 12,035 $ 5,057 Office and computer equipment 1,078 481 Leasehold improvements 1,760 1,063 Construction in progress 3,984 1,305 Total property and equipment 18,857 7,906 Less: accumulated depreciation (3,272 ) (1,305 ) Property and equipment, net $ 15,585 $ 6,601
Schedule of Finite-Lived Intangible Assets [Table Text Block]	December 31, 2022 December 31, 2021 Developed technology $ 5,000 $ 10,600 Intellectual property 80 80 Total cost 5,080 10,680 Less: accumulated amortization (60 ) (56 ) Intangible assets, net $ 5,020 $ 10,624
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Year Ending December 31, Amount 2023 $ 731 2024 731 2025 731 2026 731 2027 731 Thereafter 1,365 Total $ 5,020
Schedule of Accrued Liabilities [Table Text Block]	December 31, 2022 December 31, 2021 Accrued compensation $ 3,112 $ 2,786 Accrued clinical and manufacturing expenses 2,413 986 Accrued professional and consulting services 691 556 Accrued other expenses 1,868 736 Total $ 8,084 $ 5,064

Note 7 - Liabilities Related _2

Note 7 - Liabilities Related to Sale of Future Royalties (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]	Total liability related to sale of future royalties, start of year $ 11,522 Non-cash royalty revenue paid to HCRP (151 ) Non-cash interest expense recognized 1,305 Revaluation gain recognized (6,960 ) Total liability related to sale of future royalties, end of year 5,716 Current portion (95 ) Long-term portion $ 5,621

Note 8 - Leases (Tables)

Note 8 - Leases (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Year Ending December 31, Amount 2023 $ 4,072 2024 4,213 2025 4,356 2026 4,964 2027 5,138 Thereafter 6,649 Undiscounted total 29,392 Less: imputed interest (7,687 ) Present value of future minimum payments 21,705 Current portion of operating lease liability (2,228 ) Operating lease liability, net of current portion $ 19,477
Lease, Cost [Table Text Block]	Year Ended December 31, 2022 2021 Lease cost Operating lease cost $ 4,159 $ 2,513 Short-term lease cost 436 340 Variable lease cost 1,312 1,233 Sublease income - (36 ) Total lease cost $ 5,907 $ 4,050

Note 10 - Stockholders' Equity

Note 10 - Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Common Stock Reserved for Issuance [Table Text Block]	December 31, 2022 December 31, 2021 Options issued and outstanding 14,725,261 10,216,106 RSUs issued and outstanding 808,310 — Available for future grants of equity awards 12,074,692 5,582,742 Common stock warrants 227,434 232,434 2022 Employee Stock Purchase Plan 1,800,000 — Total 29,635,697 16,031,282
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Securities into which warrants are convertible Warrants outstanding Exercise Price Expiration Date Common Stock 44,148 $ 1.10 April 2024 Common Stock 26,515 $ 1.375 April 2024 Common Stock 29,150 $ 2.50 March 2025 Common Stock 100,532 $ 3.125 February 2025 Common Stock 16,175 $ 3.125 March 2024 Common Stock 10,914 $ 22.99 December 2026 Total 227,434

Note 11 - Equity Incentive Pl_2

Note 11 - Equity Incentive Plans (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Weighted Weighted Shares Number of Option Average Number of RSU Average Available Options Exercise RSUs Grant Date For Grant Outstanding Price Outstanding Fair Value Balance at January 1, 2021 1,230,863 6,813,033 $ 2.70 — $ — Authorized under 2019 Plan Amendment 8,900,000 — $ — — $ — Granted (5,178,438 ) 5,178,438 $ 7.09 — $ — Exercised — (1,070,921 ) $ 1.63 — $ — Forfeited 630,317 (650,054 ) $ 3.16 — $ — Canceled — (54,390 ) $ 11.98 — $ — Balance at December 31, 2021 5,582,742 10,216,106 $ 4.96 — $ — Authorized under 2019 Plan Amendment 12,000,000 — $ — — $ — Granted (7,291,935 ) 6,376,657 $ 4.10 915,278 $ 3.58 Exercised — (180,336 ) $ 1.24 — $ — Forfeited 1,625,133 (1,518,230 ) $ 6.19 (106,968 ) $ 3.62 Canceled 158,752 (168,936 ) $ 7.17 — $ — Balance at December 31, 2022 12,074,692 14,725,261 $ 4.48 808,310 $ 3.57
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Year Ended December 31, 2022 2021 Risk-free interest rate 1.62% - 4.02 % 0.91% - 1.35 % Expected term (in years) 5.42 - 6.08 5.44 - 6.08 Expected volatility 125% - 131 % 122% - 131 % Dividend yield — % — %
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Year Ended December 31, 2022 2021 Research and development $ 9,183 $ 4,304 General and administrative 4,404 4,563 Total stock-based compensation $ 13,587 $ 8,867

Note 13 - Income Taxes (Tables)

Note 13 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Year Ended December 31, 2022 2021 Current: Federal $ — $ — State 3 1 Foreign 64 106 Total Current 67 107 Deferred: Federal — — State — — Foreign — — Total Deferred — — Provision for income taxes $ 67 $ 107
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	December 31, 2022 December 31, 2021 Deferred tax assets: Net operating loss carryforwards $ 39,822 $ 30,256 Research and development tax credits 7,943 4,923 Capitalized research and development 14,260 4,016 Sale of future royalties 2,886 5,826 Lease liability 4,581 3,184 Accruals, reserves and other 5,004 3,043 Total deferred tax assets 74,496 51,248 Valuation allowance (66,323 ) (42,589 ) Deferred tax assets net of valuation allowance 8,173 8,659 Deferred tax liabilities: Intangible assets (2,614 ) (5,410 ) Right-of-use assets (5,427 ) (3,223 ) Depreciation on property and equipment (132 ) (26 ) Total deferred tax liabilities (8,173 ) (8,659 ) Net deferred tax assets $ — $ —
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Year Ended December 31, 2022 2021 U.S. federal taxes at statutory rate 21.0 % 21.0 % State taxes (net of federal benefit) 0.1 4.0 Foreign rate differential (0.3 ) 0.3 Permanently non-deductible items (1.5 ) 0.2 Tax credits 3.0 3.4 Change in valuation allowance (22.0 ) (29.3 ) Tax attributes write-off due to change in control — — Prior year true-up (0.2 ) 0.6 Other (0.2 ) (0.3 ) Provision for income taxes (0.1 )% (0.1 )%
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	Year Ended December 31, 2022 2021 Beginning Balance $ 2,422 $ 1,281 Additions based on tax positions related to the current year 2,589 1,132 Increase (decreases) related to prior years’ tax positions (66 ) 9 Ending Balance $ 4,945 $ 2,422

Note 14 - Net Loss Per Share _2

Note 14 - Net Loss Per Share Attributable to Common Stockholders (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Year Ended December 31, 2022 2021 Net loss $ (107,758 ) $ (70,470 ) Shares used to compute net loss per share, basic and diluted 127,683,813 121,453,723 Net loss per share attributable to common stockholders, basic and diluted $ (0.84 ) $ (0.58 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Year Ended December 31, 2022 2021 Options to purchase common stock 13,567,390 8,206,137 Restricted stock unit to purchase common stock 460,975 — Warrants to purchase common stock 228,725 369,043 Employee Stock Purchase Plan 392,095 — Total potentially dilutive securities excluded from denominator of the diluted earnings per share computation 14,649,185 8,575,180

Note 1 - Organization and Nat_2

Note 1 - Organization and Nature of Business (Details Textual) - USD ($) $ in Thousands			9 Months Ended	11 Months Ended	12 Months Ended
	Sep. 15, 2021	Oct. 13, 2020	Sep. 30, 2021	Sep. 13, 2021	Dec. 31, 2022	Dec. 31, 2021
Proceeds from Issuance of Common Stock					$ 17,237	$ 122,210
The October 2020 Offering [Member]
Open Market Sale Agreement, Maximum Aggregate Offering Price		$ 250,000
Payments of Stock Issuance Costs		$ 300
Open Market Sale Agreement, Sales Commission, Percentage		4.50%
Stock Issued During Period, Shares, New Issues (in shares)			13,239,839	13,932,490
Proceeds from Issuance of Common Stock			$ 127,900	$ 133,400
Proceeds from Issuance of Common Stock, Net			$ 122,200	$ 127,100
The September 2021 ATM [Member]
Open Market Sale Agreement, Maximum Aggregate Offering Price	$ 100,000
Open Market Sale Agreement, Sales Commission, Percentage	3%
Stock Issued During Period, Shares, New Issues (in shares)					8,419,700
Proceeds from Issuance of Common Stock					$ 18,000
Proceeds from Issuance of Common Stock, Net					$ 17,200

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Cash, Cash Equivalents, and Short-Term Investments, Total		$ 95,700
Net Cash Provided by (Used in) Operating Activities, Total		(94,779)	$ (59,832)
Restricted Cash, Total		2,000	0
Accounts Receivable, Allowance for Credit Loss, Ending Balance			0
Deferred Revenue, Current, Total		$ 2,000	$ 0
Developed Technology Rights [Member] | Maximum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	11 years 9 months		11 years 9 months
Intellectual Property [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	20 years		20 years

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Estimated Useful Lives (Details)	12 Months Ended
	Dec. 31, 2022
Laboratory Equipment [Member]
Laboratory equipment (in years) (Year)	5 years
Office Equipment [Member]
Laboratory equipment (in years) (Year)	3 years

Note 3 - Business Combination_2

Note 3 - Business Combination (Details Textual)	Nov. 30, 2021 USD ($)
Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed	$ 82,000
Prepaid Rent	671,000
Acquisition of Kindred BioSciences [Member]
Business Combination, Consideration Transferred, Total	$ 4,829,000

Note 3 - Business Combination -

Note 3 - Business Combination - Allocation of the Purchase Price to the Fair Value of the Respective Assets and Liabilities Acquired (Details) - USD ($) $ in Thousands	Nov. 30, 2021	Dec. 31, 2022	Dec. 31, 2021
Goodwill, Ending Balance		$ 4,508	$ 4,508
Acquisition of Kindred BioSciences [Member]
Business combination, property and equipment acquired	$ 321
Goodwill, Ending Balance	4,508
Business Combination, Consideration Transferred, Total	$ 4,829

Note 4 - Fair Value of Financ_3

Note 4 - Fair Value of Financial Instruments (Details Textual) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Fair Value, Recurring [Member]
Financial Liabilities Fair Value Disclosure, Total	$ 0	$ 0

Note 4 - Fair Value of Financ_4

Note 4 - Fair Value of Financial Instruments - Financial Assets Measured on a Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Money Market Funds [Member]
Money market funds, Fair Value	$ 30,834	$ 70,978
Fair Value, Recurring [Member]
Total assets	80,538	109,930
Fair Value, Recurring [Member] | US Treasury Securities [Member]
Investments, Fair Value Disclosure	41,542	24,997
Fair Value, Recurring [Member] | Commercial Paper, Not Included with Cash and Cash Equivalents [Member]
Investments, Fair Value Disclosure	5,674	7,491
Fair Value, Recurring [Member] | Corporate Debt Securities [Member]
Investments, Fair Value Disclosure	2,488	6,464
Fair Value, Recurring [Member] | Money Market Funds [Member]
Money market funds, Fair Value	30,834	70,978
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Total assets	30,834	70,978
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | US Treasury Securities [Member]
Investments, Fair Value Disclosure	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Commercial Paper, Not Included with Cash and Cash Equivalents [Member]
Investments, Fair Value Disclosure	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Corporate Debt Securities [Member]
Investments, Fair Value Disclosure	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]
Money market funds, Fair Value	30,834	70,978
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Total assets	49,704	38,952
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | US Treasury Securities [Member]
Investments, Fair Value Disclosure	41,542	24,997
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Commercial Paper, Not Included with Cash and Cash Equivalents [Member]
Investments, Fair Value Disclosure	5,674	7,491
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Corporate Debt Securities [Member]
Investments, Fair Value Disclosure	2,488	6,464
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Money Market Funds [Member]
Money market funds, Fair Value	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Total assets	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | US Treasury Securities [Member]
Investments, Fair Value Disclosure	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Commercial Paper, Not Included with Cash and Cash Equivalents [Member]
Investments, Fair Value Disclosure	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Corporate Debt Securities [Member]
Investments, Fair Value Disclosure	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Money Market Funds [Member]
Money market funds, Fair Value	$ 0	$ 0

Note 5 - Balance Sheet Compon_3

Note 5 - Balance Sheet Components (Details Textual) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Accounts Receivable, after Allowance for Credit Loss, Current, Total		$ 20,000	$ 71,000
Accounts Receivable, Allowance for Credit Loss, Current		0
Depreciation, Total		1,967,000	732,000
Tangible Asset Impairment Charges, Total		0
Operating Lease, Right-of-Use Asset		25,715,000	13,168,000
Amortization of Intangible Assets		1,300,000	1,700,000
Goodwill, Ending Balance		4,508,000	4,508,000
Goodwill, Impairment Loss		$ 0
Developed Technology Rights [Member]
Finite-Lived Intangible Asset, Remaining Life (Year)		6 years 10 months 24 days
Impairment of Intangible Assets (Excluding Goodwill), Total		$ 4,300,000	$ 3,000,000
Intellectual Property [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	20 years		20 years
Finite-Lived Intangible Asset, Remaining Life (Year)		5 years
Maximum [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	11 years 9 months		11 years 9 months
Facility in Burlingame, California [Member]
Operating Lease, Right-of-Use Asset	$ 15,000,000
Royalty [Member]
Accounts Receivable, after Allowance for Credit Loss, Current, Total		$ 20,000	$ 71,000

Note 5 - Balance Sheet Compon_4

Note 5 - Balance Sheet Components - Cash and Cash Equivalents and Investments (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash and cash equivalents	$ 44,013	$ 143,745
Cash, cash equivalents and restricted cash	46,013	143,745	$ 126,870
Gross Unrealized Loss	(299)	(74)
Short-term investments	49,704	22,742
Long-term investments	0	16,210
Investments and Cash	96,016	182,771
Investments and Cash, Fair Value Disclosure	95,717	182,697
US Treasury Securities [Member]
Amortized Cost	41,812	25,055
Gross Unrealized Loss	(270)	(58)
Estimated Fair Value	41,542	24,997
Short-term investments	41,542	12,022
Long-term investments	0	12,975
Commercial Paper, Not Included with Cash and Cash Equivalents [Member]
Amortized Cost	2,488	7,491
Gross Unrealized Loss	0
Estimated Fair Value	2,488	7,491
Short-term investments	2,488	7,491
Corporate Debt Securities [Member]
Amortized Cost	5,703	6,480
Gross Unrealized Loss	(29)	(16)
Estimated Fair Value	5,674	6,464
Short-term investments	5,674	3,229
Long-term investments		3,235
Cash [Member]
Cash and cash equivalents	15,179	72,767
Money market funds, Fair Value	15,179	72,767
Cash, cash equivalents and restricted cash	15,179	72,767
Money Market Funds [Member]
Cash and cash equivalents	30,834	70,978
Money market funds, Fair Value	30,834	70,978
Cash, cash equivalents and restricted cash	$ 30,834	$ 70,978

Note 5 - Balance Sheet Compon_5

Note 5 - Balance Sheet Components - Property and Equipment, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Property and equipment, gross	$ 18,857	$ 7,906
Less: accumulated depreciation	(3,272)	(1,305)
Property and equipment, net	15,585	6,601
Laboratory Equipment [Member]
Property and equipment, gross	12,035	5,057
Office Equipment [Member]
Property and equipment, gross	1,078	481
Leasehold Improvements [Member]
Property and equipment, gross	1,760	1,063
Construction in Progress [Member]
Property and equipment, gross	$ 3,984	$ 1,305

Note 5 - Balance Sheet Compon_6

Note 5 - Balance Sheet Components - Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Intangible assets, gross	$ 5,080	$ 10,680
Less: accumulated amortization	(60)	(56)
Intangible assets, net	5,020	10,624
Developed Technology Rights [Member]
Intangible assets, gross	5,000	10,600
Intellectual Property [Member]
Intangible assets, gross	$ 80	$ 80

Note 5 - Balance Sheet Compon_7

Note 5 - Balance Sheet Components - Estimated Future Amortization Expense (Details) $ in Thousands	Dec. 31, 2022 USD ($)
2023	$ 731
2024	731
2025	731
2026	731
2027	731
Thereafter	1,365
Total	$ 5,020

Note 5 - Balance Sheet Compon_8

Note 5 - Balance Sheet Components - Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Accrued compensation	$ 3,112	$ 2,786
Accrued clinical and manufacturing expenses	2,413	986
Accrued professional and consulting services	691	556
Accrued other expenses	1,868	736
Total	$ 8,084	$ 5,064

Note 6 - Revenue (Details Textu

Note 6 - Revenue (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Revenue from Contract with Customer, Including Assessed Tax	$ 107,000	$ 892,000
Income Tax Expense (Benefit), Total	$ 67,000	107,000
Foreign Tax Authority [Member] | National Tax Agency, Japan [Member]
Royalty Withholding Tax	5%
Income Tax Expense (Benefit), Total	$ 5,000	44,000
Royalty [Member] | Daiichi Sankyo Collaberation and License Agreement [Member]
Royalty Percentage	4%
Revenue from Contract with Customer, Including Assessed Tax	$ 0
Non Cash Royalty Revenue [Member]
Revenue from Contract with Customer, Including Assessed Tax	107,000	879,000
Non Cash Royalty Revenue [Member] | Daiichi Sankyo Collaberation and License Agreement [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 107,000	$ 879,000

Note 7 - Liabilities Related _3

Note 7 - Liabilities Related to Sale of Future Royalties (Details Textual) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Apr. 30, 2016	Dec. 31, 2022	Dec. 31, 2021
Re-valuation Gain Recognized		$ 7	$ 3.8
HCRP [Member]
Proceeds from Sale of Future Royalties, Net	$ 20
Royalty Interest Due Each Year	$ 3
Royalty Interest, Percentage of Additional Royalties Due Each Year	15%
Royalty Interest, Additional Royalties Due Each Year	$ 1

Note 7 - Liabilities Related _4

Note 7 - Liabilities Related to Sale of Future Royalties - Deferred Revenue Activity (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Revaluation gain recognized	$ (7,000)	$ (3,800)
Current portion	(95)	(836)
Long-term portion	5,621	10,686
HealthCare Royalty Partners III, L.P. [Member] | Royalty Arrangement [Member]
Total liability related to sale of future royalties, start of year	11,522
Non-cash royalty revenue paid to HCRP	(151)
Non-cash interest expense recognized	1,305
Revaluation gain recognized	(6,960)
Total liability related to sale of future royalties, end of year	5,716	$ 11,522
Current portion	(95)
Long-term portion	$ 5,621

Note 8 - Leases (Details Textua

Note 8 - Leases (Details Textual) $ in Millions	Dec. 31, 2022 USD ($)	Jul. 31, 2019
Lessee, Operating Lease, Expected Tenant Improvements	$ 2.3
Operating Lease, Weighted Average Discount Rate, Percent	9.80%
Operating Lease, Weighted Average Remaining Lease Term (Year)	6 years 1 month 6 days
Short-Term Lease Commitment, Amount	$ 29.4
Lessee, Finance Lease, Number of Leases	0
Right of Use for Office and Manufacturing Facilities with Initial Terms Exceeding One Year [Member]
Lessee, Operating Lease, Number of Right-of-Use Leases	6
Operating Lease Arrangements for Facilities [Member]
Lessee, Short-term Lease, Number of Leases	2
Lease Agreements for Manufacturing Equipment with Initial Terms of One Year or Less [Member]
Lessee, Short-term Lease, Number of Leases	1
South San Francisco Real Estate [Member]
Lessee, Operating Lease, Renewal Term (Year)	8 years	5 years
September 2021 Lease for Facility in South San Francisco [Member]
Lessee, Operating Lease, Renewal Term (Year)	8 years
Facility in South San Francisco [Member]
Lessee, Operating Lease, Renewal Term (Year)	5 years
Facility in Burlingame, California [Member]
Lessee, Short-term Lease, Number of Leases	2
Lessee, Operating Lease, Renewal Term (Year)	30 months
Lessee, Operating Lease, Number of Renewal Option	2

Note 8 - Leases - Lease Liabili

Note 8 - Leases - Lease Liabilities Payment Obligations (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
2023	$ 4,072
2024	4,213
2025	4,356
2026	4,964
2027	5,138
Thereafter	6,649
Undiscounted total	29,392
Less: imputed interest	(7,687)
Present value of future minimum payments	21,705
Current portion of operating lease liability	(2,228)	$ (1,011)
Operating lease liability, net of current portion	$ 19,477	$ 11,997

Note 8 - Leases - Operating Lea

Note 8 - Leases - Operating Lease Expenses (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Operating lease cost	$ 4,159	$ 2,513
Short-term lease cost	436	340
Variable lease cost	1,312	1,233
Sublease income	0	(36)
Total lease cost	$ 5,907	$ 4,050

Note 9 - Commitments and Cont_2

Note 9 - Commitments and Contingencies (Details Textual) - USD ($) $ in Millions		12 Months Ended
	Nov. 02, 2022	Dec. 31, 2022
Himmelberg V. Vaxart, Inc. et al. [Member]
Litigation Settlement, Amount Awarded to Other Party		$ 12
Payments for Legal Settlements	$ 2
Lease for Facility in South San Francisco, California [Member]
Purchase Obligation, Total		7.9
Lessee, Operating Lease, Lease Not yet Commenced		0.4
Lessee, Operating Lease, Lease Not yet Commenced, Minimum Tenant Improvements		2.3
Payments for Tenant Improvements		1.1
Lessee, Operating Lease, Lease Not Yet Commenced, Purchase Obligation		$ 1.2

Note 10 - Stockholders' Equit_2

Note 10 - Stockholders' Equity (Details Textual) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
	Aug. 04, 2022	Dec. 31, 2022	Aug. 03, 2022	Dec. 31, 2021
Preferred Stock, Shares Authorized (in shares)		5,000,000		5,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)		$ 0.0001		$ 0.0001
Preferred Stock, Shares Outstanding, Ending Balance (in shares)		0		0
Common Stock, Shares Authorized (in shares)		250,000,000	150,000,000	150,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)		$ 0.0001		$ 0.0001
Common Stock, Increase in Shares Authorized (in shares)	100,000,000
Dividends, Total		$ 0
First Set of Warrants Expiring April 2024 [Member]
Warrant Exercise Price to be Entitled to Receive Cash Consideration, Fundamental Transaction (in dollars per share)		$ 1.10
Warrants Expiring March 2025 [Member]
Warrant Exercise Price to be Entitled to Receive Cash Consideration, Fundamental Transaction (in dollars per share)		2.50
Warrants Expiring February 2025 [Member]
Warrant Exercise Price to be Entitled to Receive Cash Consideration, Fundamental Transaction (in dollars per share)		$ 3.125

Note 10 - Stockholders' Equit_3

Note 10 - Stockholders' Equity - Shares of Common Stock Reserved for Issuance (Details) - shares	Dec. 31, 2022	Dec. 31, 2021
Common stock reserved for issuance (in shares)	29,635,697	16,031,282
Common Warrants [Member]
Common stock reserved for issuance (in shares)	227,434	232,434
Share-Based Payment Arrangement, Option [Member]
Common stock reserved for issuance (in shares)	14,725,261	10,216,106
Restricted Stock Units (RSUs) [Member]
Common stock reserved for issuance (in shares)	808,310	0
Future Grants of Equity Awards [Member]
Common stock reserved for issuance (in shares)	12,074,692	5,582,742
ESPP [Member]
Common stock reserved for issuance (in shares)	1,800,000	0

Note 10 - Stockholders' Equit_4

Note 10 - Stockholders' Equity - Summary of Warrants Outstanding (Details)	Dec. 31, 2022 $ / shares shares
Securities into which warrants are convertible (in shares)	227,434
First Set of Warrants Expiring September 2024 [Member]
Securities into which warrants are convertible (in shares)	44,148
Securities into which warrants are convertible (in dollars per share) | $ / shares	$ 1.10
First Set of Warrants Expiring April 2024 [Member]
Securities into which warrants are convertible (in shares)	26,515
Securities into which warrants are convertible (in dollars per share) | $ / shares	$ 1.375
Second Set of Warrants Expiring April 2024 [Member]
Securities into which warrants are convertible (in shares)	29,150
Securities into which warrants are convertible (in dollars per share) | $ / shares	$ 2.50
Warrants Expiring March 2025 [Member]
Securities into which warrants are convertible (in shares)	100,532
Securities into which warrants are convertible (in dollars per share) | $ / shares	$ 3.125
Warrants Expiring February 2025 [Member]
Securities into which warrants are convertible (in shares)	16,175
Securities into which warrants are convertible (in dollars per share) | $ / shares	$ 3.125
Warrants Expiring March 2024 [Member]
Securities into which warrants are convertible (in shares)	10,914
Securities into which warrants are convertible (in dollars per share) | $ / shares	$ 22.99

Note 11 - Equity Incentive Pl_3

Note 11 - Equity Incentive Plans (Details Textual) - USD ($)			3 Months Ended	12 Months Ended
	Jun. 16, 2021	Jun. 15, 2021	Jun. 30, 2021	Dec. 31, 2022	Dec. 31, 2021	Aug. 04, 2022	Dec. 31, 2020	Jun. 08, 2020	Apr. 23, 2019
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)				14,725,261	10,216,106		6,813,033
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)				$ 4.48	$ 4.96		$ 2.70
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)				6 years 7 months 6 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value				$ 148,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number (in shares)				5,881,798
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)				$ 3.88
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term (Year)				5 years 4 months 6 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value				$ 133,000
Share Price (in dollars per share)				$ 0.96
Proceeds from Stock Options Exercised				$ 223,000	$ 1,745,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)				180,336	1,070,921
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value				$ 481,000	$ 6,200,000
Common Stock, Capital Shares Reserved for Future Issuance (in shares)				29,635,697	16,031,282
Share-Based Payment Arrangement, Expense				$ 13,587,000	$ 8,867,000
Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)				$ 3.57	$ 0		$ 0
Common Stock, Capital Shares Reserved for Future Issuance (in shares)				808,310	0
Restricted Stock Units (RSUs) [Member] | Employees [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)				850,061
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)				4 years
Restricted Stock Units (RSUs) [Member] | Director [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)				29,500
Restricted Stock Units (RSUs) [Member] | Director [Member] | The Day Before Annual Stockholders Meeting, or Grant Date Anniversary [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)				35,717
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)				$ 4.10	$ 6.49
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount				$ 28,100,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)				2 years 10 months 24 days
Common Stock, Capital Shares Reserved for Future Issuance (in shares)				14,725,261	10,216,106
Share-Based Payment Arrangement, Option [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term (Year)				5 years 5 months 1 day	5 years 5 months 8 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate				125%	122%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate				1.62%	0.91%
Share-Based Payment Arrangement, Option [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term (Year)				6 years 29 days	6 years 29 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate				131%	131%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate				4.02%	1.35%
Share-Based Payment Arrangement, Option [Member] | Former Chairman of the Board [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Month)		3 months
Share-Based Payment Arrangement, Option [Member] | Former Chairman of the Board [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Month)	10 months
Stock Options with Accelerated Vesting [Member] | Former Chairman of the Board [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Accelerated Vesting, Number (in shares)				100,000
Share-Based Payment Arrangement, Plan Modification, Incremental Cost			$ 1,300,000
The 2019 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)	16,900,000					28,900,000		8,000,000	1,600,000
The 2022 ESPP [Member]
Share Price (in dollars per share)				$ 0.46
Common Stock, Capital Shares Reserved for Future Issuance (in shares)				1,800,000		1,800,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term (Year)				6 months
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate				84.66%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate				4.60%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate				0%
Share-Based Payment Arrangement, Expense				$ 0

Note 11 - Equity Incentive Pl_4

Note 11 - Equity Incentive Plans - Summary of Stock Option Transactions (Details) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Shares available for grant, balance (in shares)	5,582,742	1,230,863
Number of options outstanding, beginning balance (in shares)	10,216,106	6,813,033
Weighted average exercise price, balance (in dollars per share)	$ 4.96	$ 2.70
Shares availabe for grant, 2019 Plan Amendment (in shares)	12,000,000	8,900,000
Shares available for grant, granted (in shares)	(7,291,935)	(5,178,438)
Number of options outstanding, granted (in shares)	6,376,657	5,178,438
Weighted average exercise price, granted (in dollars per share)	$ 4.10	$ 7.09
Number of options outstanding, exercised (in shares)	(180,336)	(1,070,921)
Weighted average exercise price, exercised (in dollars per share)	$ 1.24	$ 1.63
Shares available for grant, forfeited (in shares)	1,625,133	630,317
Number of options outstanding, forfeited (in shares)	(1,518,230)	(650,054)
Weighted average exercise price, forfeited (in dollars per share)	$ 6.19	$ 3.16
Shares available for grant, canceled (in shares)	158,752	0
Number of options outstanding, canceled (in shares)	(168,936)	(54,390)
Weighted average exercise price, canceled (in dollars per share)	$ 7.17	$ 11.98
Shares available for grant, balance (in shares)	12,074,692	5,582,742
Number of options outstanding, balance (in shares)	14,725,261	10,216,106
Weighted average exercise price, balance (in dollars per share)	$ 4.48	$ 4.96
Restricted Stock Units (RSUs) [Member]
Weighted average exercise price, balance (in dollars per share)	0	0
Weighted average exercise price, granted (in dollars per share)	3.58	0
Weighted average exercise price, exercised (in dollars per share)	0	0
Weighted average exercise price, forfeited (in dollars per share)	3.62	0
Weighted average exercise price, canceled (in dollars per share)	$ 0	0
Granted (in shares)	915,278
Exercised (in shares)	0
Forfeited (in shares)	(106,968)
Weighted average exercise price, balance (in dollars per share)	$ 3.57	$ 0
Balance at December 31, 2022 (in shares)	808,310

Note 11 - Equity Incentive Pl_5

Note 11 - Equity Incentive Plans - Assumptions of Options (Details) - Share-Based Payment Arrangement, Option [Member]	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Minimum [Member]
Risk-free interest rate	1.62%	0.91%
Expected term (in years) (Year)	5 years 5 months 1 day	5 years 5 months 8 days
Expected volatility	125%	122%
Maximum [Member]
Risk-free interest rate	4.02%	1.35%
Expected term (in years) (Year)	6 years 29 days	6 years 29 days
Expected volatility	131%	131%

Note 11 - Equity Incentive Pl_6

Note 11 - Equity Incentive Plans - Total Stock-based Compensation Recognized for Options (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share-Based Payment Arrangement, Expense	$ 13,587	$ 8,867
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expense	9,183	4,304
General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expense	$ 4,404	$ 4,563

Note 12 - Benefit Plan (Details

Note 12 - Benefit Plan (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay		3%
Defined Contribution Plan, Cost	$ 658,000	$ 288,000
Defined Contribution Plan, Administrative Expense	$ 19,000	$ 14,000

Note 13 - Income Taxes (Details

Note 13 - Income Taxes (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2019	Dec. 31, 2020
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21%	21%	21%
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$ 23,700	$ 20,600
Unrecognized Tax Benefits, Ending Balance	4,945	2,422		$ 1,281
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total	0	0
Domestic Tax Authority [Member]
Operating Loss Carryforwards	162,100	115,900
Domestic Tax Authority [Member] | Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount	6,900	3,100
State and Local Jurisdiction [Member]
Operating Loss Carryforwards	$ 85,000	84,800
Open Tax Year	2016 2017 2018 2019 2020 2021
State and Local Jurisdiction [Member] | Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount	$ 7,000	$ 5,000
Foreign Tax Authority [Member] | Australian Taxation Office [Member]
Operating Loss Carryforwards	$ 6,200

Note 13 - Income Taxes - Compon

Note 13 - Income Taxes - Components of Income Tax Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Current:
Federal	$ 0	$ 0
State	3	1
Foreign	64	106
Total Current	67	107
Deferred:
Federal	0	0
State	0	0
Foreign	0	0
Total Deferred	0	0
Provision for income taxes	$ 67	$ 107

Note 13 - Income Taxes - Comp_2

Note 13 - Income Taxes - Components of Deferred Tax Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Net operating loss carryforwards	$ 39,822	$ 30,256
Research and development tax credits	7,943	4,923
Capitalized research and development	14,260	4,016
Sale of future royalties	2,886	5,826
Lease liability	4,581	3,184
Accruals, reserves and other	5,004	3,043
Total deferred tax assets	74,496	51,248
Valuation allowance	(66,323)	(42,589)
Deferred tax assets net of valuation allowance	8,173	8,659
Intangible assets	(2,614)	(5,410)
Right-of-use assets	(5,427)	(3,223)
Depreciation on property and equipment	(132)	(26)
Total deferred tax liabilities	(8,173)	(8,659)
Net deferred tax assets	$ 0	$ 0

Note 13 - Income Taxes - Reconc

Note 13 - Income Taxes - Reconciliation of Effective Tax Rate (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2019
U.S. federal taxes at statutory rate	21%	21%	21%
State taxes (net of federal benefit)	0.10%	4%
Foreign rate differential	(0.30%)	0.30%
Permanently non-deductible items	(1.50%)	0.20%
Tax credits	3%	3.40%
Change in valuation allowance	(22.00%)	(29.30%)
Tax attributes write-off due to change in control	0%	0%
Prior year true-up	(0.20%)	0.60%
Other	(0.20%)	(0.30%)
Provision for income taxes	(0.10%)	(0.10%)

Note 13 - Income Taxes - Unreco

Note 13 - Income Taxes - Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Beginning Balance	$ 2,422	$ 1,281
Additions based on tax positions related to the current year	2,589	1,132
Decrease related to prior years’ tax positions	(66)
Increase related to prior years’ tax positions		9
Ending Balance	$ 4,945	$ 2,422

Note 14 - Net Loss Per Share _3

Note 14 - Net Loss Per Share Attributable to Common Stockholders (Details Textual) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)
Dilutive Securities, Effect on Basic Earnings Per Share, Total	$ 0

Note 14 - Net Loss Per Share _4

Note 14 - Net Loss Per Share Attributable to Common Stockholders - Calculation of Basic and Diluted Net (Loss) Income Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Net loss	$ (107,758)	$ (70,470)
Shares used to compute net loss per share, basic and diluted (in shares)	127,683,813	121,453,723
Net loss per share attributable to common stockholders, basic and diluted (in dollars per share)	$ (0.84)	$ (0.58)

Note 14 - Net Loss Per Share _5

Note 14 - Net Loss Per Share Attributable to Common Stockholders- Summary of Antidilutive Securities (Details) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Potentially dilutive securities excluded from denominator of the diluted earnings per share computation (in shares)	14,649,185	8,575,180
Share-Based Payment Arrangement, Option [Member]
Potentially dilutive securities excluded from denominator of the diluted earnings per share computation (in shares)	13,567,390	8,206,137
Restricted Stock Units (RSUs) [Member]
Potentially dilutive securities excluded from denominator of the diluted earnings per share computation (in shares)	460,975	0
Warrant [Member] | Common Stock [Member]
Potentially dilutive securities excluded from denominator of the diluted earnings per share computation (in shares)	228,725	369,043
Employee Stock Purchase Plan [Member]
Potentially dilutive securities excluded from denominator of the diluted earnings per share computation (in shares)	392,095	0

Note 15 - Subsequent Events (De

Note 15 - Subsequent Events (Details Textual) - USD ($) $ in Thousands	2 Months Ended	12 Months Ended
	Mar. 08, 2023	Dec. 31, 2022	Dec. 31, 2021
Proceeds from Issuance of Common Stock		$ 17,237	$ 122,210
The September 2021 ATM [Member]
Stock Issued During Period, Shares, New Issues (in shares)		8,419,700
Proceeds from Issuance of Common Stock		$ 18,000
Subsequent Event [Member] | The September 2021 ATM [Member]
Stock Issued During Period, Shares, New Issues (in shares)	1,362,220
Proceeds from Issuance of Common Stock	$ 1,500